Dividends & Buybacks ·
CytoSorbents Corporation effected a one-for-twenty (1:20) reverse stock split of its common stock, effective September…
CTSOCytosorbents Corp
CytoSorbents Corporation effected a one-for-twenty (1:20) reverse stock split of its common stock, effective September 8, 2026. The transaction was approved by shareholders at the August 13, 2026 Annual Meeting and finalized via a Certificate of Amendment filed with Delaware on September 3, 2026. Prior to the split, there were 63,022,020 shares outstanding. The split proportionally adjusted outstanding options and warrants while maintaining the $0.001 par value and total authorized share count. Fractional shares were rounded up to the nearest whole share. CytoSorbents Corporation operates in the medical device industry, specializing in blood purification technologies.